Comments
Jubilant Life Sciences’ subsidiary Jubilant Pharma will acquire the radio-pharmacy business of US-based Triad Isotopes for an undisclosed sum.
“Jubilant Pharma Ltd (JPL)... through one of its wholly owned subsidiaries, has signed an asset purchase agreement with Triad Isotopes Inc and its parent, Isotope Holdings Inc (Triad) to acquire substantially all of the assets which comprise the radio-pharmacy business of Triad,” Jubilant Life Sciences said in a BSE filing.
It further said: “The acquisition will be funded through JPL’s internal accruals and is likely to be earnings accretive in the first full year of operations. Triad recorded revenues in excess of $225 million in the calendar year 2016 with positive EBITDA.”
Jubilant Life Sciences said Triad operates the second largest radio-pharmacy network in the US with more than 50 pharmacies, distributing nuclear medicine products to the largest national GPOs, regional health systems, standalone imaging centres, cardiologists and hospitals.
“The acquisition is a strategic fit to Jubilant’s niche nuclear medicine business and will provide Jubilant with direct access to hospital networks with ability to deliver more than 3 million patient doses annually through approximately 1,700 customers,” Jubilant Life Sciences said.
The company said the completion of the transaction is subject to customary closing conditions, including contract, regulatory and other approvals.
Shares of Jubilant Life Sciences were trading 3.49 per cent higher at Rs 760 on the BSE
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.